CTOs on the Move

HistoWiz

www.histowiz.com

 
HistoWiz is an innovative company dedicated to accelerating pathology-based research. HistoWiz provides fast, global access to digital whole-slide images, online collaboration tools, low-cost data management, and experimental pathology expertise. The web-based platform accelerates information exchange among medical scientists and research pathologists. HistoWiz`s mission is to fight cancer cooperatively instead of individually by connecting scientists and pathologists for online collaboration.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.histowiz.com
  • Advanced Biotechnology Park 760 Parkside Avenue
    Brooklyn, NY USA 11226
  • Phone: 347.221.1020

Executives

Name Title Contact Details

Jobs

Chief Technology Officer

HistoWiz New York County, NY
The Chief Technology Officer (CTO) is responsible for overseeing all technical aspects of the company. The CTO will work closely with the CEO to develop the long-term tech vision of the company. The CTO is responsible for managing the entire code base and will be the primary developer for the ...

Similar Companies

Codagenix

Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells.

Timtec

Timtec is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Protox Therapeutics Inc

Protox Therapeutics Inc is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turning Point Therapeutics

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Advanced Solutions

Advanced Solutions designs and manufactures biofabrication systems for next-generation drug discovery, personalized medicine, and regenerative therapeutics.